Skip to main content
SpringerLink
Log in

Naringenin Cocrystals Prepared by Solution Crystallization Method for Improving Bioavailability and Anti-hyperlipidemia Effects

  • Research Article
  • Published:
AAPS PharmSciTech Aims and scope Submit manuscript

Abstract

Naringenin exerts anti-inflammatory, hypolipidemic, and hepatoprotective effects; however, it shows low oral bioavailability because of poor water solubility. In this work, cocrystals of naringenin were formed to address these issues. Using the solution crystallization method, various naringenin cocrystals were prepared with different cocrystal coformers, including naringenin-nicotinamide, naringenin-isonicotinamide, naringenin-caffeine, naringenin-betaine, and naringenin-L-proline. The formation of these cocrystals was assayed by using DSC, XRD, and FT-IR spectroscopy. The stoichiometric ratio of naringenin and the CCFs in the corresponding cocrystals was investigated by NMR. The solubility of naringenin, as well as its dissolution rate, was markedly improved by forming cocrystals. The oral bioavailability of naringenin administered as naringenin-L-proline and naringenin-betaine cocrystals was achieved significantly greater than that of pure naringenin (p < 0.05). In particular, the Cmax of naringenin-L-proline and naringenin-betaine cocrystals were 2.00-fold and 3.35-fold higher, and the AUC of naringenin-L-proline and naringenin-betaine cocrystals were 2.39-fold and 4.91-fold, respectively, higher than pure naringenin in rats. With the naringenin-betaine cocrystals for oral delivery, the drug distribution in the liver was significantly increased compared to pure naringenin. Accordingly, the naringenin-betaine cocrystals showed improved anti-hyperlipidemia effects on the C57 BL/6J PNPLA3 I148M transgenic mouse hyperlipidemia model. Collectively, cocrystal formation is a promising way to increase the bioavailability of naringenin for treating hyperlipidemia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11
Fig. 12

Similar content being viewed by others

References

  1. Kawabata Y, Wada K, Nakatani M, Yamada S, Onoue S. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications. Int J Pharm. 2011;420:1–10.

    Article  CAS  PubMed  Google Scholar 

  2. Cascone S. Modeling and comparison of release profiles: effect of the dissolution method. Eur J Pharm Sci. 2017;106:352–61.

    Article  CAS  PubMed  Google Scholar 

  3. Hu J, Johnston KP, Williams RO. Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs. Drug Dev Ind Pharm. 2004;30:233–45.

    Article  PubMed  CAS  Google Scholar 

  4. Blagden N, de Matas M, Gavan PT, York P. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv Drug Deliv Rev. 2007;59:617–30.

    Article  CAS  PubMed  Google Scholar 

  5. Chun NH, Lee MJ, Song GH, Chang KY, Kim CS, Choi GJ. Combined anti-solvent and cooling method of manufacturing indomethacin-saccharin (IMC-SAC) co-crystal powders. J Cryst Growth. 2014;408:112–8.

    Article  CAS  Google Scholar 

  6. Karashima M, Sano N, Yamamoto S, Arai Y, Yamamoto K, Amano N, et al. Enhanced pulmonary absorption of poorly soluble itraconazole by micronized cocrystal dry powder formulations. Eur J Pharm Biopharm. 2017;115:65–72.

    Article  CAS  PubMed  Google Scholar 

  7. Otaki T, Tanabe Y, Kojima T, Miura M, Ikeda Y, Koide T, et al. In situ monitoring of cocrystals in formulation development using low-frequency Raman spectroscopy. Int J Pharm. 2018;542:56–65.

    Article  CAS  PubMed  Google Scholar 

  8. Renugadevi J, Prabu SM. Cadmium-induced hepatotoxicity in rats and the protective effect of naringenin. Exp Toxicol Pathol. 2010;62:171–81.

    Article  CAS  PubMed  Google Scholar 

  9. Yoon H, Kim TW, Shin SY, Park MJ, Yong Y, Kim DW, et al. Design, synthesis and inhibitory activities of naringenin derivatives on human colon cancer cells. Bioorg Med Chem Lett. 2013;23:232–8.

    Article  CAS  PubMed  Google Scholar 

  10. Subramanian P, Arul D. Attenuation of NDEA-induced hepatocarcinogenesis by naringenin in rats. Cell Biochem Funct. 2013;31:511–7.

    Article  CAS  PubMed  Google Scholar 

  11. Ekambaram G, Rajendran P, Magesh V, Sakthisekaran D. Naringenin reduces tumor size and weight lost in N-methyl-N-nitro-N-nitrosoguanidine-induced gastric carcinogenesis in rats. Nutr Res. 2008;28:106–12.

    Article  CAS  PubMed  Google Scholar 

  12. Francis AR, Shetty TK, Bhattacharya RK. Modulating effect of plant flavonoids on the mutagenicity of N-methyl-N-nitro-N-nitrosoguanidine. Carcinogenesis. 1989;10:1953–5.

    Article  CAS  PubMed  Google Scholar 

  13. Leonardi T, Vanamala J, Taddeo SS, Davidson LA, Murphy ME, Patil BS, et al. Turner, apigenin and naringenin suppress colon carcinogenesis through the aberrant crypt stage in azoxymethane-treated rats. Exp Biol Med(Maywood). 2010;235:710–7.

    Article  CAS  Google Scholar 

  14. Arul D, Subramanian P. Inhibitory effect of naringenin (citrus flavonone) on N-nitrosodiethylamine induced hepatocarcinogenesis in rats. Biochem Biophys Res Commun. 2013;434:203–9.

    Article  CAS  PubMed  Google Scholar 

  15. Cavia-Saiz M, Busto MD, Pilar-Izquierdo MC, Ortega N, Perez-Mateos M, Muñiz P. Antioxidant properties, radical scavenging activity and biomolecule protection capacity of flavonoid naringenin and its glycoside naringin: a comparative study. J Sci Food Agric. 2010;90:1238–44.

    Article  CAS  PubMed  Google Scholar 

  16. Goldwasser J, Cohen PY, Lin W, Kitsberg D, Balaguer P, Polyak SJ, et al. Naringenin inhibits the assembly and long-term production of infectious hepatitis C virus particles through a PPAR-mediated mechanism. J Hepatol. 2011;55:963–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Nahmias Y, Goldwasser J, Casali M, van Poll D, Wakita T, Chung RT, et al. Apolipoprotein B dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin. Hepatology. 2008;47:1437–45.

    Article  CAS  PubMed  Google Scholar 

  18. Ortiz-Andrade RR, Sánchez-Salgado JC, Navarrete-Vázquez G, Webster SP, Binnie M, García-Jiménez S, et al. Antidiabetic and toxicological evaluations of naringenin in normoglycaemic and NIDDM rat models and its implications on extra-pancreatic glucose regulation. Diabetes Obes Metab. 2018;10:1097–104.

    Article  CAS  Google Scholar 

  19. Seeram NP, Zhang Y, Henning SM, Lee R, Niu Y, Lin G, et al. Pistachio skin phenolics are destroyed by bleaching resulting in reduced antioxidative capacities. J Agric Food Chem. 2006;54:7036–40.

    Article  CAS  PubMed  Google Scholar 

  20. Zygmunt K, Faubert B, MacNeil J, Tsiani E. Naringenin, a citrus flavonoid, increases muscle cell glucose uptake via AMPK. J Mol Struct. 2010;398:178–83.

    CAS  Google Scholar 

  21. Wang MJ, Chao PDL, Hou YC, Hsiu SL. Pharmacokinetics and conjugation metabolism of naringin and naringenin in rats after single dose and multiple dose administrations. J Food Drug Anal. 2006;14:247–53.

    CAS  Google Scholar 

  22. Kanaze F, Bounartzi M, Georgarakis M, Niopas I. Pharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjects. Eur J Clin Nutr. 2007;61:472–7.

    Article  CAS  PubMed  Google Scholar 

  23. Xu XR, Yu HT, Hang L, Shao Y, Ding SH, Yang XW. Preparation of naringenin/ β-cyclodextrin complex and its more potent alleviative effect on choroidal neovascularization in rats. Biomed Res Int. 2014;2014:623509.

    PubMed  PubMed Central  Google Scholar 

  24. Gera S, Talluri S, Rangaraj N, Sampathi S. Formulation and evaluation of naringenin nanosuspensions for bioavailability enhancement. AAPS PharmSciTech. 2017;18:1–12.

    Article  CAS  Google Scholar 

  25. Wang Y, Wang S, Firempong CK, Zhang H, Wang M, Zhang Y, et al. Enhanced solubility and bioavailability of naringenin via liposomal nanoformulation: preparation and in vitro and in vivo evaluations. AAPS PharmSciTech. 2017;18:586–94.

    Article  PubMed  CAS  Google Scholar 

  26. Khan AW, Kotta S, Ansari SH, Sharma RK, Ali J. Enhanced dissolution and bioavailability of grapefruit flavonoid naringenin by solid dispersion utilizing fourth generation carrier. Drug Dev Ind Pharm. 2015;41:772–9.

    Article  CAS  PubMed  Google Scholar 

  27. Zhang L, Li S, Zhang P, Liu T, Li Z, Yang G, et al. Solubilities of naringin and naringenin in different solvents and dissociation constants of naringenin. J Chem Eng Data. 2015;60:932–40.

    Article  CAS  Google Scholar 

  28. Variankaval N, Wenslow R, Murry J, Hartman R, Helmy R, Kwong E, et al. Preparation and solid-state characterization of nonstoichiometric cocrystals off a phosphodiesterase-IV inhibitor annul L-tartaric acid. Cryst Growth Des. 2006;6:690–700.

    Article  CAS  Google Scholar 

  29. Fang T, Wang Y, Ma Y, Su W, Bai Y, Zhao P. A rapid LC/MS/MS quantitation assay for naringin and its two metabolites in rats plasma. J Pharm Biomed Anal. 2006;40:454–9.

    Article  CAS  PubMed  Google Scholar 

  30. Pi J, Wang S, Li W, Kebebe D, Zhang Y, Zhang B, et al. A nano-cocrystal strategy to improve the dissolution rate and oral bioavailability of baicalein. Asian J Pharm Sci. 2018;3:57.

    Google Scholar 

  31. Pinto SS, Diogo HP. Thermochemical study of two anhydrous polymorphs of caffeine. J Chem Thermodyn. 2006;38:1515–22.

    Article  CAS  Google Scholar 

  32. Kang Y, Gu J, Hu X. Syntheses, structure characterization and dissolution of two novel cocrystals of febuxostat. J Mol Struct. 2017;1130:480–6.

    Article  CAS  Google Scholar 

  33. Thakuria R, Delori A, Jones W, Lipert MP, Roy L, Rodríguez-Hornedo N. Pharmaceutical cocrystals and poorly soluble drugs. Int J Pharm. 2013;453:101–25.

    Article  CAS  PubMed  Google Scholar 

  34. Vasisht K, Chadha K, Karan M, Bhalla Y, Chadha R, Khullar S, et al. Co-crystals of hesperitin: structural, pharmacokinetic and pharmacodynamic evaluation. Cryst Growth Des. 2017;17:2386–405.

    Article  CAS  Google Scholar 

  35. Semalty A, Semalty M, Singh D, Rawat MSM. Preparation and characterization of phospholipid complexes of naringenin for effective drug delivery. J Incl Phenom Macrocycl Chem. 2010;67:253–60.

    Article  CAS  Google Scholar 

  36. Gao Y, Zu H, Zhang J. Enhanced dissolution and stability of adefovir dipivoxil by cocrystal formulation. J Pharm Pharmacol. 2011;63:483–90.

    Article  CAS  PubMed  Google Scholar 

  37. Hong C, Xie Y, Yao Y, Li G, Yuan X, Shen H. A novel strategy for pharmaceutical cocrystal generation without knowledge of stoichiometric ratio: myricetin cocrystals and a ternary phase diagram. Pharm Res. 2015;32:47–60.

    Article  CAS  PubMed  Google Scholar 

  38. Huang Y, Zhang B, Gao Y, Zhang J, Shi L. Baicalein-nicotinamide cocrystal with enhanced solubility, dissolution, and oral bioavailability. J Pharm Sci. 2014;103:2330–7.

    Article  CAS  PubMed  Google Scholar 

  39. Luo YH, Sun BW. Pharmaceutical co-crystals of pyrazinecarboxamide (PZA) with various carboxylic acids: crystal-lography, hirshfeld surfaces, and dissolution study. Cryst Growth Des. 2013;13:2098–106.

    Article  CAS  Google Scholar 

  40. Maddileti D, Jayabun SK, Nangia A. Soluble cocrystals of the xanthine oxidase inhibitor febuxostat. Cryst Growth Des. 2013;13:3188–96.

    Article  CAS  Google Scholar 

  41. Zhang X, Sun F, Zhang T, Jia J, Su H, Wang C, et al. Three pharmaceuticals cocrystals of adefovir: syntheses, structures and dissolution study. J Mol Struct. 2015;1100:395–400.

    Article  CAS  Google Scholar 

  42. Li J, Wang L, Ye YQ, Fu X, Ren Q, Zhang H, et al. Improving the solubility of dexlansoprazole by cocrystallization with isonicotinamide. Eur J Pharm Sci. 2016;85:47–52.

    Article  CAS  PubMed  Google Scholar 

  43. Smith AJ, Kavuru P, Wojtas L, Zaworotko MJ, Shytle RD. Cocrystals of quercetin with improved solubility and oral bioavailability. Mol Pharm. 2011;8:1867–76.

    Article  CAS  PubMed  Google Scholar 

  44. Childs SL, Kandi P, Lingireddy SR. Formulation of a danazol cocrystal with controlled supersaturation plays an essential role in improving bioavailability. Mol Pharm. 2013;10:3112–27.

    Article  CAS  PubMed  Google Scholar 

  45. Liu MY, Hong C, Yao YS, Shen HY, Ji G, Li GW, et al. Development of a pharmaceutical cocrystal with solution crystallization technology: preparation, characterization, and evaluation of myricetin-proline cocrystals. Eur J Pharm Biopharm. 2016;107:151–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This study was funded and supported by the National Natural Science Foundation of China (81673612).

Author information

Author notes

  1. Wenxia Cui and Zehui He contributed equally to this work.

Authors and Affiliations

  1. Department of Pharmaceutical Sciences, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China

    Wenxia Cui, Zehui He, Yongtai Zhang, Qiangyuan Fan & Nianping Feng

Authors
  1. Wenxia Cui
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zehui He
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yongtai Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Qiangyuan Fan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nianping Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nianping Feng.

Ethics declarations

Conflict of Interest

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cui, W., He, Z., Zhang, Y. et al. Naringenin Cocrystals Prepared by Solution Crystallization Method for Improving Bioavailability and Anti-hyperlipidemia Effects. AAPS PharmSciTech 20, 115 (2019). https://doi.org/10.1208/s12249-019-1324-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1208/s12249-019-1324-0

KEY WORDS

Search

Navigation